Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection
NCT ID: NCT01002833
Last Updated: 2010-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2010-04-30
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PfA
Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
Exposure to Plasmodium falciparum infected mosquitoes
Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
PfB
Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
Exposure to Plasmodium falciparum infected mosquitoes
Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
NF54
Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
Exposure to Plasmodium falciparum infected mosquitoes
Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure to Plasmodium falciparum infected mosquitoes
Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* General good health based on history and clinical examination
* Negative pregnancy test
* Use of adequate contraception for females
* All volunteers have to sign the informed consent form following proper understanding of the meaning and procedures of the study
* Volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the study
* Willingness to undergo a Pf sporozoite challenge
* Agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 till Day T +3)
* Reachable by mobile phone during the whole study period
* Available to attend all study visits
* Agreement to refrain from blood donation to Sanquin or for other purposes, during the course of the study
* Willingness to undergo an HIV, hepatitis B and C test
* Negative urine toxicology screening test at screening visit and day before challenge
* Willingness to take a curative regimen of Malarone®
Exclusion Criteria
* Plans to travel to endemic malaria areas during the study period
* Previous participation in any malaria vaccine study and/or positive serology for Pf
* Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers
* History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
* History of arrhythmia's or prolonged QT-interval
* Positive family history in 1st and 2nd degree relatives for cardiac disease \< 50 years old
* An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
* Body Mass Index (BMI) below 18 or above 30 kg/m2
* Any clinically significant deviation from the normal range in biochemistry or haematology blood tests or in urine analysis
* Positive HIV, HBV or HCV tests
* Participation in any other clinical study within 30 days prior to the onset of the study
* Volunteers enrolled in any other clinical study during the study period
* Pregnant or lactating women
* Volunteers unable to give written informed consent
* Volunteers unable to be closely followed for social, geographic or psychological reasons
* Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study
* A history of psychiatric disease
* Known hypersensitivity for anti-malaria drugs
* History of severe reactions or allergy to mosquito bites
* The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months before study onset (inhaled and topical corticosteroids are allowed) and during the study period
* Contra-indications to Malarone® including treatment taken by the volunteers that interfere with Malarone®
* Any confirmed or suspected immunosuppressive or immunodeficiency condition, including asplenia
* Co-workers of the departments of Medical Microbiology or Internal Medicine of the Radboud University Nijmegen Medical Centre or Leiden University Medical Center
* A history of sickle cell, thalassaemia trait and G6PD deficiency
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leiden University Medical Center
OTHER
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Leiden University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leiden University Medical Center
Leiden, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ. The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection. PLoS Comput Biol. 2017 Jan 12;13(1):e1005255. doi: 10.1371/journal.pcbi.1005255. eCollection 2017 Jan.
Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, Scholzen A, Heinrichs MJ, Siebelink-Stoter R, Graumans W, van Gemert GJ, Teelen K, Vos MW, Nganou-Makamdop K, Borrmann S, Rozier YP, Erkens MA, Luty AJ, Hermsen CC, Sim BK, van Lieshout L, Hoffman SL, Visser LG, Sauerwein RW. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis. 2013 Feb 15;207(4):656-60. doi: 10.1093/infdis/jis725. Epub 2012 Nov 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TIP1
Identifier Type: -
Identifier Source: org_study_id